GSK is witnessing increased sales growth of its Specialty Medicines unit, a trend expected to continue through the rest of 2025.

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

July is observed as Sarcoma Awareness Month. Sarcoma is a rare type of cancer that affects muscles, fat, nerves, and other connective tissues. About 15,000 people in the U.S.

GSK plc (NYSE: GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival (PFS) readout ahead of its potential U.S. return in multiple myeloma this ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with combo regimens. Read more here.

GSK said the European Medicines Agency's committee responsible for human medicines has recommended the approval for its Blenrep drug. The U.K. pharma company on Friday said an approval decision by ...

GSK plc announced the approval of Blenrep combinations by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...

GSK reported that the trials showed significant and clinically meaningful results for progression-free survival with Blenrep’s combinations.

GSK's Blenrep approved in the U.K. for multiple myeloma after strong phase 3 data showing improved survival in DREAMM-7 and DREAMM-8 trials.